Using Transcranial Magnetic Stimulation to Treat Misophonia
A Transcranial Magnetic Stimulation Approach to Treat Misophonia
This study is testing if a brain treatment called TMS can help people with misophonia become more tolerant to certain annoying sounds.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 55 Years |
| Sex | All |
| Sponsor | Icahn School of Medicine at Mount Sinai Academic / other |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT06960083 on ClinicalTrials.gov |
What this trial studies
This project aims to evaluate the effectiveness of parietal transcranial magnetic stimulation (TMS) in individuals suffering from misophonia. A total of 60 participants will undergo two sessions of TMS, one designed to inhibit and the other to excite brain activity in the parietal region. Participants will complete computerized tasks before and after each session while their EEG, heart rate, and skin temperature are monitored. The goal is to determine if TMS can enhance tolerance to specific sound triggers associated with misophonia.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 55 who experience heightened sensitivity to specific sounds, leading to emotional distress.
Not a fit: Patients with psychiatric conditions or neurological diseases that affect their ability to participate in the study may not benefit from this intervention.
Why it matters
Potential benefit: If successful, this approach could significantly improve the quality of life for individuals with misophonia by reducing their sensitivity to sound triggers.
How similar studies have performed: While the use of TMS in treating various conditions has shown promise, the specific application for misophonia is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Hypersensitive to presence of a specific sound, which may be accompanied by irritation, anger/outbursts, or fear. * Must be between the ages of 18 - 55. * Must be fluent in English since the study's instructions, surveys, and tasks will be in English. Exclusion Criteria: * Axis I Psychiatric condition, past or present, as defined in DSM-V. * Disability or medical condition that prohibits completion of study. Participants must be able to complete all study procedures to ensure optimal conditions for data analysis. * Central Nervous System (CNS) disease, such as history of brain abnormalities (e.g., neoplasms, subarachnoid cysts), cerebrovascular disease, infectious disease (e.g., abscess), or other neurological diseases, history of head trauma (defined as loss of consciousness\>3 min), or history of seizures without a resolved etiology. CNS disease and drugs that act in the peripheral or central nervous system are likely to have effects on patterns of neural activity. * Recent or regular use of psychotropic medication (e.g., amitriptyline for migraines). * Recent use of drugs of abuse. * Presence of any mental implants in the head. * Pregnant or lactating.
Where this trial is running
New York, New York
- Mount Sinai West — New York, New York, United States (Recruiting)
Study contacts
- Principal investigator: Parul Jain, PhD — Icahn School of Medicine at Mount Sinai
- Study coordinator: Shama Patel
- Email: shama.patel@mssm.edu
- Phone: 347-670-4878
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.